IRF8 and acute myeloid leukemia: BET inhibitor resistant AML cells use available factors, such as PU.1 and interferon regulatory factor 8 (IRF8), to nucleate the different enhancers, facilitating remodelling of regulatory pathways that rapidly restore expression of survival genes (92, 118).